Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
9.22
-0.73 (-7.34%)
Nov 7, 2024, 4:00 PM EST - Market closed

Company Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.

The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.

Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Daxor Corporation
Daxor logo
Country United States
Founded 1970
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 37
CEO Michael Feldschuh

Contact Details

Address:
109 Meco Lane
Oak Ridge, Tennessee 37830
United States
Website daxor.com

Stock Details

Ticker Symbol DXR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000027367
CUSIP Number 239467103
ISIN Number US2394671034
Employer ID 13-2682108

Key Executives

Name Position
Michael Richard Feldschuh Chairman, President and Chief Executive Officer
Jonathan Adam Feldschuh Chief Scientific Officer and Director
Robert J. Michel CPA, CPA, M.B.A. Chief Financial Officer, Chief Compliance Officer and Corporate Secretary
Linda Cooper Vice President of Development and Operations
Kathryn A. Kornafel Senior Vice President of Marketing and Commercial Development
Guido Manzo Vice President of Sales
Jean Oertel Senior Vice President Commercialization and Customer Experience
Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 10, 2024 N-PX Annual Report of proxy voting record of management investment companies
Aug 29, 2024 NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
Aug 29, 2024 N-CSRS Filing
Aug 23, 2024 40-17G Filing
Aug 16, 2024 N-2 Filing
Jul 18, 2024 8-K Current Report
Jun 21, 2024 DEF 14A Other definitive proxy statements
Jun 5, 2024 8-K Current Report
May 30, 2024 NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
Apr 3, 2024 40-17F2 Filing